Place · Level 3 · Condition
Hyperuricemia
中国成人 ~ 13% · 男 > 7 / 女 > 6 mg/dL · 90% 是排泄差不是合成多 · 多数无症状不必用药 · 与痛风、尿酸结石 / CKD / 代谢综合征同源
Last updated
Story path
Chapter 1
Threshold · epi · vs gout
Threshold · epi · vs gout
Hyperuricemia is a lab finding, not a disease. The clinical definition is straightforward: serum urate (SUA) > 7 mg/dL (420 µmol/L) in men, > 6 mg/dL (360 µmol/L) in women. This threshold isn't a 'lower is better' health target — it's the level at which SUA in plasma approaches its physical saturation point (~ 6.8 mg/dL). Above that, crystals can form.
SUA ≠ gout — the first thing this atlas wants to be clear about:
People with high SUA outnumber people with gout by far: in Chinese adults, hyperuricemia prevalence is about 13.3% (men 19.4% / women 7.9%), while true gout prevalence is only 1.1% (Liu 2015 meta-analysis)Roughly only one in ten people with hyperuricemia will actually experience a gout flare in their lifetime — most simply carry an elevated SUA on lab reports forever, with no crystal depositionThat's why this island gives hyperuricemia its own scene: panicking at a red lab value (→ strict diet → repeated clinic visits) is a common overreaction
Global trend + younger ages:
Chinese hyperuricemia prevalence has nearly doubled in 30 years, tracking the sugary-drink curve + urbanisation + obesity (see the atlas gout scene)In the 1980s it was largely a 50+ male diagnosis; in 2020s China, men 18-35 are the fastest-growing demographicUS NHANES shows ~ 20% adult prevalence, rising alongside metabolic syndromePremenopausal women have markedly lower SUA than men (estrogen promotes renal excretion); the gap narrows quickly after menopause — see the atlas perimenopause island
Why most people are surprised by the result:
Hyperuricemia is almost entirely asymptomatic — unlike high glucose (thirst, fatigue) or high blood pressure (occasional headache)It is usually 'incidentally discovered' at routine check-ups, at the first gout flare, or at the first kidney-stone presentationIn China, SUA is part of standard adult check-ups; in the US it is not, and patients need to request it
Common misreadings of a high SUA report:
'Mildly elevated (7.5 mg/dL) = must start medication now': no — see the ULT decision scene below'I have a family history, my SUA is high, so I'll get gout': increased risk, not inevitability — long-term management starts at family history + high SUA + ≥ 1 confirmed flare'I've never had a flare, so I can ignore this': hyperuricemia has consequences beyond gout — see the multi-organ scene'Lower is always better': not really — very low SUA (< 2 mg/dL) has been linked to neurodegenerative risk; the clinical target is 'below saturation + no flares', not 'as low as possible'
SUA ≠ gout — the first thing this atlas wants to be clear about:
People with high SUA outnumber people with gout by far: in Chinese adults, hyperuricemia prevalence is about 13.3% (men 19.4% / women 7.9%), while true gout prevalence is only 1.1% (Liu 2015 meta-analysis)Roughly only one in ten people with hyperuricemia will actually experience a gout flare in their lifetime — most simply carry an elevated SUA on lab reports forever, with no crystal depositionThat's why this island gives hyperuricemia its own scene: panicking at a red lab value (→ strict diet → repeated clinic visits) is a common overreaction
Global trend + younger ages:
Chinese hyperuricemia prevalence has nearly doubled in 30 years, tracking the sugary-drink curve + urbanisation + obesity (see the atlas gout scene)In the 1980s it was largely a 50+ male diagnosis; in 2020s China, men 18-35 are the fastest-growing demographicUS NHANES shows ~ 20% adult prevalence, rising alongside metabolic syndromePremenopausal women have markedly lower SUA than men (estrogen promotes renal excretion); the gap narrows quickly after menopause — see the atlas perimenopause island
Why most people are surprised by the result:
Hyperuricemia is almost entirely asymptomatic — unlike high glucose (thirst, fatigue) or high blood pressure (occasional headache)It is usually 'incidentally discovered' at routine check-ups, at the first gout flare, or at the first kidney-stone presentationIn China, SUA is part of standard adult check-ups; in the US it is not, and patients need to request it
Common misreadings of a high SUA report:
'Mildly elevated (7.5 mg/dL) = must start medication now': no — see the ULT decision scene below'I have a family history, my SUA is high, so I'll get gout': increased risk, not inevitability — long-term management starts at family history + high SUA + ≥ 1 confirmed flare'I've never had a flare, so I can ignore this': hyperuricemia has consequences beyond gout — see the multi-organ scene'Lower is always better': not really — very low SUA (< 2 mg/dL) has been linked to neurodegenerative risk; the clinical target is 'below saturation + no flares', not 'as low as possible'
机制 · 为什么结晶偏偏挑大脚趾和后半夜
回到那杯糖水。同一杯水放进冰箱, 会比放在灶台边更早析出结晶——溶解度是随温度下降的。血浆里的尿酸也守同一条规矩。人体各处的温度并不一样: 大脚趾离心脏最远、常年暴露在外, 皮温比躯干低一截。于是同一个血尿酸浓度, 走到那里就更贴近饱和线。再叠上两件事——关节腔里血流慢, 尿酸被冲走的速度本来就低; 夜里躺平之后, 关节液里的水被周围组织慢慢吸走, 剩下的液体反而更浓——三个因素撞在一起, 大脚趾就成了全身最容易先越线的那个点。
这一步接上之后, 两件读者常觉得奇怪的事就都有了解释:
痛风为什么多在后半夜到清晨发作: 那正是核心体温最低、关节液最浓的几个小时。它不是白天没注意, 是那几个小时的局部条件最靠近饱和线为什么同样的化验值有人发作、有人不发作: 决定发作的从来不是血里那个数字本身, 而是某一个具体关节的局部环境有没有越过它自己的那条线。血里的数字只是把所有关节往线上推的一个共同压力
为什么这件事值得单独理解一遍
因为它一次性拆掉了两种常见的错误推理:
我数字没超标, 所以不可能是痛风 —— 局部条件可以让一个看起来正常的血值在某个关节里越线; 急性发作时血尿酸甚至常常是暂时下降的我数字很高, 所以得赶紧压下去 —— 高只是提高了概率, 并不代表结晶已经在长。真正决定要不要用药的是有没有已经发生的后果 (发作、痛风石、结石), 见本岛 ULT 决策幕
换句话说, 这条饱和线是一条物理线, 不是一条道德线。它讲的是溶解度, 不是自律。
数字 · 有多少人高 · 有多少人真痛风
SUA ≠ 痛风, 这点先说清:高尿酸的人远多于痛风的人: 中国成人高尿酸约 13.3% (男 19.4% / 女 7.9%), 而真正发作过痛风的只有 1.1% (Liu 2015 meta)换个角度看, 十个高尿酸的人里, 大概只有一个会在某个时点真的发作痛风 —— 大多数人一辈子化验单上 SUA 偏高, 但关节腔里从未沉积结晶所以看到化验单上一个红字就以为自己要痛风了、赶紧严格戒口、焦虑跑医院, 是很常见的过度反应
越来越普遍, 也越来越年轻: 这些年高尿酸的人明显变多、发病年龄也在往下走, 和含糖饮料、久坐、肥胖一条曲线往上走 (见 atlas gout 幕)。女性绝经前普遍比男性低——雌激素帮着肾把尿酸排掉——绝经后差距很快缩小 (见 atlas perimenopause 岛)。
雌激素那一句其实是个机制线索
它不是女性体质好这种模糊说法。雌激素作用的位置很具体: 它压低肾小管上负责把尿酸捞回血里的那套回收装置的活性, 回收少了, 随尿排掉的就多了。所以绝经前女性的基线血尿酸普遍低一截, 靠的是出口开得更大, 而不是生成得更少。
这也预告了下一幕的主线: 决定一个人尿酸高不高的, 主要是排泄这一侧的设定。雌激素只是众多能拨动这个设定的因素之一——胰岛素、利尿药、脱水、酮体, 全都拨在同一套装置上。
为什么很多人查出来都吃一惊:
高尿酸几乎完全无症状 — 不像血糖高会口渴乏力, 不像血压高会头晕它通常在常规体检、痛风第一次发作、肾结石第一次发作时被意外发现这也是为什么 30 岁以后, 中国常规体检会把 SUA 加入基础项目; 美国体检默认不查, 需要主动要求
Chapter 2
Mechanism · XO + excretion
Mechanism · XO + excretion
Understanding why SUA is high means looking at production and excretion as two legs. Most people assume 'high SUA = I eat too much purine,' but clinically about 90% of hyperuricemia is under-excretion, not over-production.
Production side · purine → xanthine → urate:
About 70% of body urate is endogenous (apoptosis + DNA turnover + energy metabolism); 30% is dietaryThe last two steps (hypoxanthine → xanthine → urate) are both catalysed by xanthine oxidase (XO) — this is why allopurinol and febuxostat both work by inhibiting XO (see the ULT scene)A key human-vs-other-mammal difference: uricase became a pseudogene ~ 15 million years ago in our lineage — we cannot, like dogs, further degrade urate into more soluble allantoin. So urate accumulates in blood and waits for excretion
Excretion side · kidney + gut:
~ 2/3 renal (urine)~ 1/3 enteric (gut microbial metabolism + stool)The renal route is the dominant lever. In the tubule, three transporters decide whether urate is reclaimed or excreted
Three transporters · the source of individual variation:
URAT1 (SLC22A12): distal-tubule urate reabsorption channel. For most people, the SUA set-point is essentially set hereGLUT9 (SLC2A9): bidirectional transporter, mainly affects tubular reabsorptionABCG2: gut + renal efflux of urate. Loss-of-function variants are common in East Asian populations and are a major genetic basis for early-onset hyperuricemia in China / Japan / KoreaCombined, variation in these three genes explains most of the 'same diet / same BMI, why is my urate high and his isn't?' puzzles
Production side · purine → xanthine → urate:
About 70% of body urate is endogenous (apoptosis + DNA turnover + energy metabolism); 30% is dietaryThe last two steps (hypoxanthine → xanthine → urate) are both catalysed by xanthine oxidase (XO) — this is why allopurinol and febuxostat both work by inhibiting XO (see the ULT scene)A key human-vs-other-mammal difference: uricase became a pseudogene ~ 15 million years ago in our lineage — we cannot, like dogs, further degrade urate into more soluble allantoin. So urate accumulates in blood and waits for excretion
Excretion side · kidney + gut:
~ 2/3 renal (urine)~ 1/3 enteric (gut microbial metabolism + stool)The renal route is the dominant lever. In the tubule, three transporters decide whether urate is reclaimed or excreted
Three transporters · the source of individual variation:
URAT1 (SLC22A12): distal-tubule urate reabsorption channel. For most people, the SUA set-point is essentially set hereGLUT9 (SLC2A9): bidirectional transporter, mainly affects tubular reabsorptionABCG2: gut + renal efflux of urate. Loss-of-function variants are common in East Asian populations and are a major genetic basis for early-onset hyperuricemia in China / Japan / KoreaCombined, variation in these three genes explains most of the 'same diet / same BMI, why is my urate high and his isn't?' puzzles
机制 · 肾小管里的三道闸门: 为什么有人天生排得慢
先记住一件反直觉的事: 肾脏并不是把尿酸滤掉就完事了。尿酸分子很小, 走到肾小球那一层几乎被全部滤进原尿——滤过这一步人人一样, 不是个体差异的来源。差异发生在下一段: 原尿流过肾小管的时候, 管壁上排着一列闸门, 会把刚滤出去的尿酸再捞回血里。捞回来的比例高得离谱, 滤出去的绝大部分最后又回到了血里, 真正随尿排掉的只是一个零头。
所以排尿酸快不快 这件事, 实际上等于回收闸门开得多大。你天生把闸门开得大一点, 血里就一直留着更多尿酸; 开得小一点, 同样的饭桌你就是排得掉。
闸门一 · URAT1 (基因 SLC22A12) —— 主回收口
它长在肾小管靠后一段的管腔面, 也就是正对着尿流 的那一侧。它干的活是一次交换: 把管腔里的一个尿酸分子拽进细胞, 同时把细胞里的一个有机酸吐到管腔里。这是一台逆流搬运机——尿酸被从要排掉 的那一侧, 搬回要留下 的那一侧。
多数人血尿酸的设定点就是在这里定下来的。URAT1 天生活性偏高的人回收得更彻底, 基线血尿酸就更高。注意: 这跟他昨晚吃了多少嘌呤无关, 是出厂设置。
这台机器还一次解释了两件临床上常见的事:
促排泄药 (丙磺舒、苯溴马隆这一类) 为什么能降尿酸: 它们做的事就是去堵住 URAT1 这个口。回收少了, 随尿排掉的自然多了——所以它降的是留下来的量, 不是生成的量, 和堵 XO 的别嘌醇走的是完全不同的一条路胰岛素为什么会推高尿酸: 高胰岛素会让这一侧的回收更卖力 (见代谢综合征幕)。于是胰岛素抵抗的人尿酸高, 根子不在他吃了什么, 在于这台回收机被踩得更狠——这也是为什么减腰围 比戒海鲜 有效得多
闸门二 · GLUT9 (基因 SLC2A9) —— 后门
URAT1 把尿酸拽进肾小管细胞之后, 尿酸还得从细胞的另一侧 (贴着血管那一面) 出去, 才算真正回到血里。负责开这道后门的就是 GLUT9。
这就是为什么这两个闸门必须一起看: URAT1 是前门, GLUT9 是后门, 前门把尿酸收进来、后门把它送回血里, 两道门串成一条完整的回收流水线。任何一道天生偏弱, 这条流水线就漏, 尿酸反而更容易被排掉——GLUT9 功能明显偏弱的人表现出来的是血尿酸偏低, 正好是这条流水线开太小的另一端。
闸门三 · ABCG2 —— 唯一往外扔的那个
前两个都是往回收, ABCG2 的方向恰好相反: 它把尿酸主动泵出去, 既装在肾上, 也装在肠壁上。前面说的大约三分之一走肠道 就是这么发生的——不是尿酸随粪便被动带走, 而是肠壁上的这台泵在往肠腔里扔。
ABCG2 功能减低的变异在东亚人群里相当常见, 它的表现方式很特别: 肠道那条出口先被堵住, 尿酸只好全压给肾。于是即使这个人的肾一切正常, 血尿酸也会一路走高。这就是中国、日本、韩国年纪轻轻就查出高尿酸、而且常常一家好几口都高的重要遗传基础。
把三道闸门连起来读
现在回头看开头那句绝大多数高尿酸是排泄不够、而不是生成太多, 它就不再是一条需要背下来的结论了:
食物嘌呤只占尿酸来源的一小部分, 而且这一部分还被内源合成稀释掉肾小球滤过那一步人人一样, 不产生差异真正的个体差异全部堆在最后一段: 回收 (URAT1 + GLUT9) 与外排 (ABCG2) 的天生比例
于是同一桌火锅吃下去, 有人尿酸一路走高、有人纹丝不动 这件事就有了机制解释, 而不是人家自制力比你好。
也顺带说清了这一岛反复强调的那条优先级: 戒海鲜内脏动的是那一小块饮食来源, 而减腰围、戒含糖饮料动的是胰岛素——胰岛素恰好直接踩在 URAT1 这台回收机上。前者在拧一个小阀门, 后者在动整条流水线的总开关。
生成端 · 尿酸从哪来 + 人类为什么会囤它
生成端 · 嘌呤 → 黄嘌呤 → 尿酸:体内尿酸大约 70% 来自内源 (细胞凋亡 + DNA 周转 + 能量代谢产物), 30% 来自食物嘌呤嘌呤的最后两步: 次黄嘌呤 → 黄嘌呤 → 尿酸, 两步都由黄嘌呤氧化酶 (XO, xanthine oxidase) 催化这就是为什么 ULT 药物里别嘌醇、非布司他都靠抑制 XO 来降 SUA (见 ULT 幕)人类与狗、猪 / 大多数哺乳动物的关键差别: 尿酸酶 (uricase) 基因在 1500 万年前进化失活 — 我们不能像狗那样把尿酸进一步分解成更可溶的尿囊素, 所以尿酸在血里直接囤着等排泄
丢掉尿酸酶这件事, 是这一岛所有麻烦的总开关
狗、猫、牛的血里也天天在产尿酸, 但它们身上还留着尿酸酶这台机器, 会把尿酸继续拆成尿囊素——尿囊素好溶得多, 顺着尿就走了。对它们来说尿酸只是流水线中间的一个半成品, 从来堆不到饱和线, 所以它们基本不会得痛风。
我们这一支的祖先把这台机器弄丢了, 于是同一条流水线在人身上断在了倒数第二步: 尿酸成了终点产物, 出口只剩原样排掉 这一条。这一件事决定了这一岛后面所有内容的形状——核心矛盾永远是排得出去吗, 而不是生成得太多吗。
它也解释了一件临床上看着很怪的事: 化疗后的溶瘤综合征那种急症里, 有一种叫拉布立酶的药特别管用, 而它的原理就是把丢掉的那台尿酸酶重新给你一份, 直接把已经堆在血里的尿酸拆成尿囊素。它绕开了整条肾小管排泄通路, 所以起效比堵 XO 快得多——代价是它是一个外源蛋白, 只能短期急用。
Phenotyping + diet limits + drug effects
'Over-production vs under-excretion' clinical phenotyping (24-h urine urate):Under-excretion ~ 90%: 24-h urine urate < 800 mg / < 600 mg on a purine-restricted dietOver-production ~ 10%: high 24-h urine urate + high SUA. Seen in lymphoma / leukaemia chemotherapy (tumour lysis syndrome — emergency) / rare enzyme defects (Lesch-Nyhan) / severe obesity / heavy alcohol useThis phenotyping is not routine — useful only for refractory gout, recurrent stones, or drug selection
Why 'just diet' has limited impact:
Of the dietary 30%, much comes from plant purines, which do not significantly raise gout risk (Choi 2004 NEJM)The 70% endogenous urate doesn't go away when you go vegetarianThe real lever for most readers is reducing insulin resistance + waist circumference + cutting sugary drinks (all improve excretion) — not the 1980s textbook 'no seafood, no organs, no tofu, no spinach' list
Drugs / states with hidden effects on excretion:
Thiazide + loop diuretics: directly ↓ excretion → the most common 'pressed BP, raised SUA' source in clinicLow-dose aspirin (< 1 g/day): ↓ excretion; paradoxically high-dose aspirin promotes excretion, but high-dose isn't used clinicallyCiclosporin + tacrolimus: post-transplant hyperuricemia is very commonChronic lead exposure: historical 'saturnine gout' from lead (rare now, but old pipes / industrial exposure still exist)Dehydration + post-exercise lactate ↑: competes with urate for tubular excretion → transient SUA riseStarvation / very-low-calorie / keto induction: ketones compete for tubular excretion → SUA spikes → can trigger a gout flare. This is the classic 'lost weight too fast and had my first flare' story
Atlas linkbacks: `fructose-metabolism/khk` L4 (fructose → AMP → urate generation) · `gout` (same island) · `kidney-stones` (uric-acid stones = 10-15% of all stones) · `endocrine/metabolic-syndrome` (insulin activates URAT1 reabsorption, so less urate leaves → high insulin = high urate).
Chapter 3
Beyond gout · multi-organ
Beyond gout · multi-organ
The clinical concern with hyperuricemia isn't only 'will I get gout?'. There are three under-recognised long-term chains — particularly poorly recognised in young Chinese men.
Chain 1 · Kidney:
Uric-acid stones: 10-15% of all kidney stones; unlike typical calcium-oxalate stones, they crystallise easily at urine pH < 5.5, appear low-density but visible on CT, and are nearly radiolucent on plain X-ray — which is why some patients with 'flank pain + haematuria but negative X-ray' are misdiagnosed for years. See the atlas `kidney-stones` sceneChronic urate nephropathy: long-term high SUA → urate crystal deposition in renal interstitium → chronic inflammation → tubulo-interstitial damage → gradual eGFR decline. Not inevitable, but patients with SUA > 10 mg/dL long-term show clearly accelerated CKD progressionAcute urate nephropathy (emergency): chemotherapy-induced tumour lysis syndrome (TLS) / severe dehydration + heavy alcohol / rare enzyme defects → SUA spikes → crystals block tubules → acute kidney injury. Emergency — see the red-flag sceneThe causality is partial: acute is clearly causal; chronic is partly causal in observational studies but Mendelian randomisation suggests SUA's causal effect on CKD is weaker than the observed association — meaning a large portion of 'high SUA + CKD' reflects shared metabolic background (hypertension + IR + MetSyn) acting on both organs
Chain 2 · Cardiovascular:
Observational links to hypertension, heart failure, CHD, and stroke — overall 'association + plausible mechanism + causality not fully established'Mechanism candidates: high SUA → endothelial dysfunction + oxidative stress + renin-angiotensin activation + microvascular inflammationKey clinical data: the CARES 2018 trial showed febuxostat had higher cardiovascular mortality vs allopurinol (not a test of treating hyperuricemia per se, but a reminder that 'urate-lowering drug effects on cardiovascular outcomes' are not neutral)Clinical implication: the guidelines disagree, and the disagreement is the information. ACR 2020 conditionally recommends *against* urate-lowering therapy for asymptomatic hyperuricaemia, while the Chinese Society of Endocrinology's 2024 update recommends first-line urate-lowering therapy for it (especially SU >= 9 mg/dL or with cardiovascular / metabolic comorbidity). So 'no major guideline recommends it' was wrong; what is true is that treating SUA as an independent cardiovascular target has not reached consensus
Chain 1 · Kidney:
Uric-acid stones: 10-15% of all kidney stones; unlike typical calcium-oxalate stones, they crystallise easily at urine pH < 5.5, appear low-density but visible on CT, and are nearly radiolucent on plain X-ray — which is why some patients with 'flank pain + haematuria but negative X-ray' are misdiagnosed for years. See the atlas `kidney-stones` sceneChronic urate nephropathy: long-term high SUA → urate crystal deposition in renal interstitium → chronic inflammation → tubulo-interstitial damage → gradual eGFR decline. Not inevitable, but patients with SUA > 10 mg/dL long-term show clearly accelerated CKD progressionAcute urate nephropathy (emergency): chemotherapy-induced tumour lysis syndrome (TLS) / severe dehydration + heavy alcohol / rare enzyme defects → SUA spikes → crystals block tubules → acute kidney injury. Emergency — see the red-flag sceneThe causality is partial: acute is clearly causal; chronic is partly causal in observational studies but Mendelian randomisation suggests SUA's causal effect on CKD is weaker than the observed association — meaning a large portion of 'high SUA + CKD' reflects shared metabolic background (hypertension + IR + MetSyn) acting on both organs
Chain 2 · Cardiovascular:
Observational links to hypertension, heart failure, CHD, and stroke — overall 'association + plausible mechanism + causality not fully established'Mechanism candidates: high SUA → endothelial dysfunction + oxidative stress + renin-angiotensin activation + microvascular inflammationKey clinical data: the CARES 2018 trial showed febuxostat had higher cardiovascular mortality vs allopurinol (not a test of treating hyperuricemia per se, but a reminder that 'urate-lowering drug effects on cardiovascular outcomes' are not neutral)Clinical implication: the guidelines disagree, and the disagreement is the information. ACR 2020 conditionally recommends *against* urate-lowering therapy for asymptomatic hyperuricaemia, while the Chinese Society of Endocrinology's 2024 update recommends first-line urate-lowering therapy for it (especially SU >= 9 mg/dL or with cardiovascular / metabolic comorbidity). So 'no major guideline recommends it' was wrong; what is true is that treating SUA as an independent cardiovascular target has not reached consensus
MetSyn comorbidity + pregnancy + how to use
Chain 3 · Metabolic syndrome + MASLD comorbidity:High SUA / hyperglycaemia / dyslipidaemia / hypertension / central obesity / fatty liver form the metabolic-syndrome 'six pack', mutually reinforcing (see atlas `endocrine/metabolic-syndrome` + `nafld`)Bidirectional mechanism: high insulin → activates URAT1 reabsorption → less urate excreted → ↑ SUA (insulin resistance drives hyperuricemia); and fructose → hepatic KHK → AMP → ↑ urate while fructose → ↑ visceral fat → ↑ IR, forming a positive feedback loopClinical practice: when a check-up flags high SUA, also assess waist + BP + fasting glucose + HbA1c + TG + HDL + liver enzymes. Looking at SUA alone is wasteful
Pregnancy-related (subset):
Preeclampsia + pregnancy-induced hypertension: high SUA is one of the early biomarkers; not a treatment target, but a 'monitor closely' signalAny pregnancy with the triad of high SUA + hypertension + proteinuria requires immediate obstetric evaluation
How to use this information:
When you see a high SUA on a lab report, don't only worry about future gout — treat it as a metabolic-health flag. It's often one of the earliest signs that insulin resistance is approaching, sometimes earlier than fasting glucoseThe real intervention is waist + sugary drinks + exercise + sleep — these change the upstream driver, not just the lab valueHigh SUA is not a 'diagnosis to panic about', but it's also not a 'meaningless red digit on the report'
Chapter 4
Diet leverage · counterintuitive
Diet leverage · counterintuitive
Real dietary priorities for hyperuricemia look nothing like the 1980s textbook. The actual levers are a small set, and 'no spinach, no tofu' isn't on it.
Lever 1 · Sugary drinks + juice + bubble tea:
The most disruptive finding in gout / hyperuricemia diet science of the past 20 yearsChoi 2008 BMJ (HPFS men): SSDs ≥ 1/day → gout risk ↑ 85%, ≥ 2/day ↑ 102%; still significant after adjusting for BMI + activity + purine intakeChoi 2010 JAMA (women): SSDs ≥ 1/day → risk ↑ 74%; 100% fruit juice also ↑ 41%Imamura 2015 BMJ meta: SSDs + juice consistently raise T2D risk — same driver shared with hyperuricemiaStanhope 2009 RCT: a single large fructose-sweetened beverage → SUA ↑ 0.5-1.5 mg/dL within 30-60 minutesMechanism in atlas `fructose-metabolism/khk` L4: fructose → hepatic KHK → adenosine triphosphate: The cell's universal energy currency — almost everything that costs energy spends it. burned → AMP → urate. Unlike glucokinase, KHK has no energy-state feedback — fructose is always acceptedSingle-largest practical ROI: swap daily milk tea / cola / sweetened coffee for unsweetened tea / Americano / sparkling water
Lever 1 · Sugary drinks + juice + bubble tea:
The most disruptive finding in gout / hyperuricemia diet science of the past 20 yearsChoi 2008 BMJ (HPFS men): SSDs ≥ 1/day → gout risk ↑ 85%, ≥ 2/day ↑ 102%; still significant after adjusting for BMI + activity + purine intakeChoi 2010 JAMA (women): SSDs ≥ 1/day → risk ↑ 74%; 100% fruit juice also ↑ 41%Imamura 2015 BMJ meta: SSDs + juice consistently raise T2D risk — same driver shared with hyperuricemiaStanhope 2009 RCT: a single large fructose-sweetened beverage → SUA ↑ 0.5-1.5 mg/dL within 30-60 minutesMechanism in atlas `fructose-metabolism/khk` L4: fructose → hepatic KHK → adenosine triphosphate: The cell's universal energy currency — almost everything that costs energy spends it. burned → AMP → urate. Unlike glucokinase, KHK has no energy-state feedback — fructose is always acceptedSingle-largest practical ROI: swap daily milk tea / cola / sweetened coffee for unsweetened tea / Americano / sparkling water
证据 · 含糖饮料那几项队列与 RCT · 为什么偏偏是果糖
第一杠杆背后的数据:Choi 2008 BMJ (HPFS 男性): 含糖饮料 ≥ 1/天 → 痛风风险 ↑ 85%, ≥ 2/天 ↑ 102%; 调整 BMI + 体力活动 + 嘌呤摄入后仍显著Choi 2010 JAMA (女性): 含糖饮料 ≥ 1/天 → 风险 ↑ 74%; 100% 果汁也 ↑ 41%Imamura 2015 BMJ meta: 含糖饮料 + 果汁与 T2D 一致升风险, 与高尿酸共享驱动Stanhope 2009 RCT: 单次饮用大剂量果糖饮料后 30-60 分钟 SUA ↑ 0.5-1.5 mg/dL
最后一条尤其值得停一下: 那是一次饮用, 半小时到一小时之内就测得出来。这不是一个需要年复一年积累的慢性效应, 而是一次可以当场观察到的急性变化。
为什么偏偏是果糖, 葡萄糖不会
细胞要处理任何一种糖, 第一步都得先给它挂上一个磷酸基团——这一步要花掉一个 adenosine triphosphate: The cell's universal energy currency — almost everything that costs energy spends it.。差别在于挂磷酸的那台机器有没有刹车。
处理葡萄糖的那台激酶是带能量感应的: 细胞里 ATP 已经够多、下游产物开始堆积, 它就自己慢下来。处理果糖的 KHK (果糖激酶) 没有这个反馈——来多少处理多少, 一律先挂上磷酸再说。
于是一大杯含糖饮料下肚, 肝细胞在很短的时间里被抽掉大量 ATP。ATP 掉一格成 ADP、再掉一格成 AMP; AMP 堆到一定量, 就被推进降解通路。而那条降解通路的终点, 正好就是尿酸。
所以喝糖水会升尿酸 这件事和嘌呤含量没有半点关系: 尿酸不是从饮料里带进来的, 是你自己的肝细胞在应付果糖时把自己的能量分子拆了、拆出来的残骸。
这条链一旦接上, 三件事就顺下来了:
为什么起效那么快: 不需要经过消化、吸收、再合成, 只需要肝里那一阵能量透支为什么果汁也算: 榨掉纤维之后果糖是一次性冲进肝脏的, 和吃一个完整水果的速度完全不同为什么这条杠杆比戒海鲜大: 海鲜动的是送进来的原料, 而含糖饮料动的是你自己身上的存货——后者的量级不受你今天吃了几只虾的限制
Beer + seafood + counterintuitive plant purines
Lever 2 · Beer > spirits > red wine:Choi 2004 Lancet: beer is the strongest signal (high purines + alcohol), spirits intermediate (mainly suppress excretion), red wine weak at 1 glass/dayComplete abstinence approximately halves flare rateThe practical move for most patients is 'stop the beer first', not 'quit all alcohol immediately' — the latter rarely sticks
Lever 3 · Seafood + organ meats + some red meat:
Choi 2004 NEJM: highest vs lowest seafood quintile → gout risk ↑ 51%; red meat ↑ 41%High-purine: sardine + anchovy + herring + oyster + shrimp + crab + squid + organ meats (liver / kidney / brain)Moderate: chicken + beef + porkThis is not 'never again' — it's the association with chronic high intake. Seafood once or twice a week isn't a problem; daily hotpot organs + skewer feasts are
Counterintuitive: plant purines barely add risk:
Choi 2004 NEJM is the field's most disruptive paper: spinach / broccoli / asparagus / mushrooms / legumes — high-purine plant foods show no significant association with gout riskSoy + tofu actually reduce gout risk (protein substitution + isoflavones)This is why the atlas keeps repeating: the older 'no spinach, no tofu' advice is built on outdated purine-content tables, and modern epidemiology has overturned itPractical: do not restrict high-purine vegetables
Protective factors + mixed vitamin C evidence
Protective factors (mild but real):Cherries (Zhang 2012): equivalent of 10-12 cherries/day → flare risk ↓ 35%Coffee (Choi 2007): ≥ 4 cups/day → gout risk ↓ 40%; partially via XO inhibition + promoting excretion; prefer black / AmericanoLow-fat dairy / unsweetened yogurt (Choi 2004 NEJM + Dalbeth 2010 RCT): 240-500 mL/day associated with ~ 40% ↓ gout, and acutely lowers SUA. The most underrated single food interventionAdequate water: ≥ 2 L/day (≥ 3 L for gout / recurrent urate stones)
Vitamin C — mixed evidence:
Choi 2009 Arch Intern Med is a 20-year prospective cohort of 47,000 men (1,317 incident gout cases): higher vitamin C intake tracked lower gout risk (RR 0.83 at 500-999 mg/day total), with supplemental vitamin C significant only from 1000 mg/day. ⚠️ It has no serum-urate endpoint — the SUA-lowering half does not come from this paperLater RCT (Stamp 2013) found limited SUA reduction in established gout (~ 0.1-0.3 mg/dL)High-dose vitamin C supplements (> 1000 mg/day) associate with increased kidney-stone risk (see atlas `kidney-stones`)Practical: don't rely on vitamin C as a primary urate-lowering tool, but dietary vitamin C from food is fine
Weight loss pace + overall pattern + linkbacks
Weight loss — important but not too fast:Long-term loss (5-10% over 3-6 months) → sustained SUA reduction + fewer flaresBut rapid loss (very-low-calorie / prolonged fasting / keto induction) → ketones compete for tubular excretion → transient SUA surge → can trigger a flareIn people with a flare history, discuss bridging prophylactic ULT with the physician during a weight-loss programme
Overall dietary pattern:
DASH + Mediterranean: vegetables + whole grains + fish + nuts + low-fat dairy + sodium control — simultaneously lowers SUA + BP + T2D riskWestern pattern (high animal protein + high sugar + ultra-processed): consistently associated with high SUADon't obsess over per-food purine gram counts — overall pattern matters far more than single-food calculations
Atlas linkbacks: `gout` (same island, fuller dietary triggers) · `fructose-metabolism/khk` L4 · `ultra-processed-foods` · `kidney-stones` · `endocrine/metabolic-syndrome`.
Chapter 5
Asymptomatic · treat or not
Asymptomatic · treat or not
'My check-up shows SUA 8.5 mg/dL but I've never had gout — should I take medication?' is the single most common question in hyperuricemia clinics and the most frequent point of over-prescription.
Mainstream answer: asymptomatic hyperuricaemia (ASU) is not recommended for drug treatment (FitzGerald 2020 ACR; ⚠️ EULAR 2016 is often listed with it, but its scope is diagnosed gout and it never discusses asymptomatic hyperuricaemia):
Most people with high SUA never have a flare — treating everyone by threshold has a poor NNT and adds real drug side-effect exposureULT drugs (especially allopurinol) carry a genuine hypersensitivity risk in Asian populations (HLA-B*5801 → Stevens-Johnson / TEN, see below)'Better SUA number' ≠ 'better outcome': the CARES trial showed febuxostat lowered SUA but raised cardiovascular mortality vs allopurinol — a warning that 'good lab ≠ better patient'
ACR 2020 strongly recommends starting ULT when:
≥ 2 flares/yearAny visible tophiGout-related imaging damage (X-ray / ultrasound shows erosion / crystal deposition)CKD ≥ 3 + prior gout flareRecurrent uric-acid stones (even without gout)
ACR 2020 conditionally recommends (individualised discussion):
First flare with SUA > 9 mg/dLFirst flare with CKD ≥ 3 / uric-acid stones / stone historyThese are 'don't necessarily start immediately, but worth a serious conversation with the physician'
Mainstream answer: asymptomatic hyperuricaemia (ASU) is not recommended for drug treatment (FitzGerald 2020 ACR; ⚠️ EULAR 2016 is often listed with it, but its scope is diagnosed gout and it never discusses asymptomatic hyperuricaemia):
Most people with high SUA never have a flare — treating everyone by threshold has a poor NNT and adds real drug side-effect exposureULT drugs (especially allopurinol) carry a genuine hypersensitivity risk in Asian populations (HLA-B*5801 → Stevens-Johnson / TEN, see below)'Better SUA number' ≠ 'better outcome': the CARES trial showed febuxostat lowered SUA but raised cardiovascular mortality vs allopurinol — a warning that 'good lab ≠ better patient'
ACR 2020 strongly recommends starting ULT when:
≥ 2 flares/yearAny visible tophiGout-related imaging damage (X-ray / ultrasound shows erosion / crystal deposition)CKD ≥ 3 + prior gout flareRecurrent uric-acid stones (even without gout)
ACR 2020 conditionally recommends (individualised discussion):
First flare with SUA > 9 mg/dLFirst flare with CKD ≥ 3 / uric-acid stones / stone historyThese are 'don't necessarily start immediately, but worth a serious conversation with the physician'
ULT drug classes + early-treat
A few situations genuinely warrant early treatment:Tumour lysis syndrome (TLS) risk in chemotherapy / haematologic malignancy: emergency / prophylactic allopurinol + aggressive hydration + rasburicase if neededChronic kidney disease + recurrent uric-acid stones: even without gout, urine alkalinisation + low-dose allopurinol may be consideredRare enzyme defects (Lesch-Nyhan / HPRT deficiency): lifelong
Three drug classes:
Allopurinol — first-line: XO inhibitor. Start at 100 mg/day, titrate every 2-5 weeks to SUA target (< 6 mg/dL, < 5 in tophi patients). Cheap + extensive long-term data. **In East Asians, HLA-B*5801 genotyping is strongly recommended before prescribing**: carriers have > 100× relative risk of fatal Stevens-Johnson / TEN (FitzGerald 2020 ACR + Taiwan NHI experience); NNT_screen ≈ 1/250 to prevent one severe cutaneous reaction. If positive → switch to febuxostat or uricosuricFebuxostat — second-line: selective XO inhibitor. 40-80 mg/day, not heavily renal-dependent. CARES 2018 showed higher cardiovascular mortality vs allopurinol — FDA black-box warning; high-CV-risk patients should prefer allopurinolUricosurics (probenecid / benzbromarone / lesinurad): second-line, ↑ excretion by inhibiting URAT1. Not suitable for CKD or uric-acid stone patients (raises crystal risk)
Initiation trap + duration
ULT initiation trap — must know:When ULT drops SUA rapidly, existing intra-articular crystals partly dissolve → triggering acute flares (expected, not treatment failure)Standard practice: bridge ULT initiation with colchicine 0.5 mg × 1-2/day (or low-dose NSAID) for 3-6 monthsDo not self-discontinue ULT during the initiation flare — the most common 'treatment makes me worse' mistake
ULT duration:
Most patients lifelongA few (large weight loss + tophi resolved + 1-2 years flare-free + stable SUA at goal) can discuss tapering with the physicianDo not self-stop — recurrence rate is high
Red flags + two-line summary
Red flags · go to ER:AKI after chemotherapy + SUA spike / massive rhabdomyolysis: suggests TLS or acute urate nephropathy — emergency (aggressive fluids + allopurinol / rasburicase + urine alkalinisation + dialysis if needed)Gout flare with fever + severe joint swelling + chills: cannot rule out septic arthritis — emergency joint aspiration requiredPregnancy + high SUA + hypertension + proteinuria: preeclampsia evaluation, obstetric emergencyRash + fever + mucosal erosion + systemic symptoms 1-8 weeks after starting allopurinol / febuxostat / sulfonamides: Stevens-Johnson / TEN / DRESS — stop drug immediately and go to the ER (life-threatening, not for home observation)
Two-line summary:
Check-up shows high SUA, no flare, no stones → don't medicate; use it as a metabolic-health flag and address waist + BP + glucose + lipids + lifestyleRecurrent flares / tophi / uric-acid stones / CKD comorbidity → ULT is the evidence-based decision; discuss the right drug + HLA-B*5801 testing + bridging prophylaxis with the physician, not at the 'supplement-aisle' level
Atlas linkbacks: `gout` (acute flare + ULT detail) · `kidney-stones` (uric-acid stone management) · `fructose-metabolism/khk` L4 · `endocrine/metabolic-syndrome`.
References · 13
- Liu, R., Han, C., Wu, D., Xia, X., Gu, J., Guan, H., Shan, Z., & Teng, W. (2015). Prevalence of hyperuricemia and gout in mainland China from 2000 to 2014: a systematic review and meta-analysis. BioMed Research International, 2015, 762820. Pooled mainland-China adult hyperuricemia prevalence ~ 13.3% (men ~ 19.4%, women ~ 7.9%); gout ~ 1.1%. 10.1155/2015/762820
- Dalbeth, N., Choi, H. K., Joosten, L. A. B., Khanna, P. P., Matsuo, H., Perez-Ruiz, F., & Stamp, L. K. (2019). Gout. Nature Reviews Disease Primers, 5(1), 69. 10.1038/s41572-019-0115-y
- Choi, H. K., Atkinson, K., Karlson, E. W., Willett, W., & Curhan, G. (2004). Purine-rich foods, dairy and protein intake, and the risk of gout in men. New England Journal of Medicine, 350(11), 1093-1103. 10.1056/NEJMoa035700
- FitzGerald, J. D., Dalbeth, N., Mikuls, T., Brignardello-Petersen, R., Guyatt, G., Abeles, A. M., et al. (2020). 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care & Research, 72(6), 744-760. Strongly recommends starting urate-lowering therapy (ULT) in patients with ≥ 2 flares/year, tophi, or radiographic damage; conditionally against initiating ULT for asymptomatic hyperuricemia. Treat-to-target SUA < 6 mg/dL. 10.1002/acr.24180
- Sun, M., Lyu, Z., Wang, C., Li, Y., Zhao, D., Ran, X., et al. (2025). 2024 Update of Chinese Guidelines for Diagnosis and Treatment of Hyperuricemia and Gout Part I: Recommendations for General Patients. International Journal of Rheumatic Diseases, 28(7). Chinese Society of Endocrinology, not Rheumatology. It RECOMMENDS first-line urate-lowering therapy for asymptomatic hyperuricaemia (SU >= 9 mg/dL, or with cardiovascular / metabolic comorbidity) — the opposite of the "no guideline recommends it" line it was once cited for, and the reason ACR 2020 and this guideline are a genuine divergence. 10.1111/1756-185X.70375
- Choi, H. K., Gao, X., Curhan, G. (2009). Vitamin C Intake and the Risk of Gout in Men. Archives of Internal Medicine, 169(5), 502. A 20-year prospective cohort of 46,994 men with 1,317 incident gout cases. SERUM URATE IS NOT AN ENDPOINT here — the urate-lowering claim belongs elsewhere. Supplemental vitamin C was significant only from 1000 mg/day. 10.1001/archinternmed.2008.606
- Richette, P., Doherty, M., Pascual, E., Barskova, V., Becce, F., Castañeda-Sanabria, J., et al. (2017). 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases, 76(1), 29-42. Scope is DIAGNOSED GOUT: every overarching principle opens with "Every person with gout". It says nothing about treating asymptomatic hyperuricaemia, and it lists the cardiovascular question as unresolved on its research agenda. Do not cite it for either. 10.1136/annrheumdis-2016-209707
- Choi, H. K., & Curhan, G. (2008). Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ, 336(7639), 309-312. Health Professionals Follow-up Study: 46,393 men with no gout at baseline, 12 years of follow-up, 755 confirmed incident cases. Versus under one serving a month, 5-6 servings a week gave RR 1.29 and two or more servings a day RR 1.85. ⚠️ This is the MEN's cohort; the women's replication is choi-2010-bmj-fructose-gout (JAMA, despite that id). 10.1136/bmj.39449.819271.BE
- Choi, H. K., Willett, W., & Curhan, G. (2010). Fructose-rich beverages and risk of gout in women. JAMA, 304(20), 2270-2278. Nurses Health Study: 78,906 women with no gout at baseline followed 22 years (1984-2006), 778 confirmed incident cases by ACR survey criteria. Rising sugar-sweetened soda intake raised risk, and orange juice showed a comparable association. 10.1001/jama.2010.1638
- Choi, H. K., Atkinson, K., Karlson, E. W., Willett, W., & Curhan, G. (2004). Alcohol intake and risk of incident gout in men: a prospective study. Lancet, 363(9417), 1277-1281. 10.1016/S0140-6736(04)16000-5
- Choi, H. K., Willett, W., & Curhan, G. (2007). Coffee consumption and risk of incident gout in men: a prospective study. Arthritis & Rheumatism, 56(6), 2049-2055. 10.1002/art.22712
- Zhang, Y., Neogi, T., Chen, C., Chaisson, C., Hunter, D. J., & Choi, H. K. (2012). Cherry consumption and decreased risk of recurrent gout attacks. Arthritis & Rheumatism, 64(12), 4004-4011. 10.1002/art.34677
- Dalbeth, N., Wong, S., Gamble, G. D., Horne, A., Mason, B., Pool, B., et al. (2010). Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial. Annals of the Rheumatic Diseases, 69(9), 1677-1682. 10.1136/ard.2009.124230